282 related articles for article (PubMed ID: 27774822)
1. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.
Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
Expert Opin Ther Pat; 2017 Feb; 27(2):145-161. PubMed ID: 27774822
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.
Kettle JG; Åstrand A; Catley M; Grimster NP; Nilsson M; Su Q; Woessner R
Expert Opin Ther Pat; 2017 Feb; 27(2):127-143. PubMed ID: 27774824
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
4. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
Norman P
Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
[TBL] [Abstract][Full Text] [Related]
5. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
6. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
He X; Chen X; Zhang H; Xie T; Ye XY
Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
[TBL] [Abstract][Full Text] [Related]
7. Selective JAK inhibitors in development for rheumatoid arthritis.
Norman P
Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
[TBL] [Abstract][Full Text] [Related]
8. JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016-present).
Chen C; Lu D; Sun T; Zhang T
Expert Opin Ther Pat; 2022 Mar; 32(3):225-242. PubMed ID: 34949146
[TBL] [Abstract][Full Text] [Related]
9. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
11. Investigational Janus kinase inhibitors.
Tam CS; Verstovsek S
Expert Opin Investig Drugs; 2013 Jun; 22(6):687-99. PubMed ID: 23432430
[TBL] [Abstract][Full Text] [Related]
12. Advances in the discovery of selective JAK inhibitors.
Menet CJ; Rompaey LV; Geney R
Prog Med Chem; 2013; 52():153-223. PubMed ID: 23384668
[TBL] [Abstract][Full Text] [Related]
13. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
Rosenthal A; Mesa RA
Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.
Meyer SC; Levine RL
Clin Cancer Res; 2014 Apr; 20(8):2051-9. PubMed ID: 24583800
[TBL] [Abstract][Full Text] [Related]
16. Recent patents in the discovery of small molecule inhibitors of JAK3.
Wilson LJ
Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545
[TBL] [Abstract][Full Text] [Related]
17. Selective JAK inhibitors.
Dymock BW; Yang EG; Chu-Farseeva Y; Yao L
Future Med Chem; 2014; 6(12):1439-71. PubMed ID: 25329199
[TBL] [Abstract][Full Text] [Related]
18. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
19. Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).
Norman P
Expert Opin Ther Pat; 2014 Sep; 24(9):979-91. PubMed ID: 24990480
[TBL] [Abstract][Full Text] [Related]
20. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.
Williams NK; Bamert RS; Patel O; Wang C; Walden PM; Wilks AF; Fantino E; Rossjohn J; Lucet IS
J Mol Biol; 2009 Mar; 387(1):219-32. PubMed ID: 19361440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
